KONTOUR 2025 Annual Report: Completes Acquisition of Xi'an Salamander Biotechnology, Oral Business Revenue Reaches 3.4351 Million Yuan

Image Source: 2025 Annual Report of Xi'an KONTOUR Medical Technology Co., Ltd.

DentalGoodNews | Xi'an KONTOUR Medical Technology Co., Ltd. has released its 2025 Annual Report. The report shows that the company achieved operating revenue of 351 million yuan in 2025 (a year-on-year increase of 9.05%); the net profit attributable to shareholders of the listed company was 98.7035 million yuan (a year-on-year increase of 11.66%). The net profit after deducting Non-recurring Gains and Losses was 91.7414 million yuan, representing a year-on-year growth of 22.55%.

In terms of the Oral business, KONTOUR Medical achieved operating revenue of 3.4351 million yuan during the reporting period, marking a phased breakthrough through preliminary layout. According to a previous report by DGN, the company had announced its intention to acquire a 55.4999% equity stake in Xi'an Salamander Biotechnology Co., Ltd. (hereinafter referred to as "Xi'an Salamander Biotechnology") for 84.9825 million yuan. The report discloses that this acquisition was completed within the reporting period, enabling the company to successfully obtain absorbable biological membrane and bone repair material products in the Oral field, thereby establishing an integrated solution covering the entire dental implant process.

In the main business segments, the combined revenue from neurosurgical PEEK material and titanium material products reached 304 million yuan, accounting for 89.07% of the main business revenue. Among these, revenue from PEEK material products was 226 million yuan, a year-on-year increase of 10.01%, with its proportion of main business revenue rising to 66.23%. Additionally, maxillofacial repair products generated revenue of 10.8673 million yuan, a year-on-year increase of 1.93%.

Image Source: 2025 Annual Report of Xi'an KONTOUR Medical Technology Co., Ltd.

Regarding cash flow, the net cash flow from operating activities in 2025 was 118 million yuan, exceeding the Net Profit Attributable to Shareholders of the Parent Company. During the reporting period, the company's R&D investment was 31.9816 million yuan, accounting for 9.11% of operating revenue, a decrease of 0.08 percentage points compared to the previous year.